Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Dilutive issuance
confidence 92%
filed 2026-06-29
RedHill Biopharma filed a prospectus supplement on June 29, 2026 to increase the maximum aggregate offering amount of American Depositary Shares under an At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC. An ATM offering is an unregistered or registered equity issuance program that allows continuous sale of shares at market prices, which is dilutive to existing shareholders. This is a material capital-raising event typical of small- and mid-cap biotech companies.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-29
Item 8.01
Z Squared Inc. completed an advance under its Standby Equity Purchase Agreement (SEPA) on June 26, 2026, issuing 1,302,806 shares of common stock to YA II PN, Ltd. at $11.8351 per share for gross proceeds of approximately $15.4 million. The shares were sold in reliance on Section 4(a)(2) exemption from registration, with resale registered under Form S-1.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 93%
filed 2026-06-29
Item 1.01
Decoy Therapeutics entered into a Securities Purchase Agreement on June 26, 2026, for a private placement (PIPE) of common stock and warrants to raise approximately $3.5 million in upfront gross proceeds at $5.91 per share, plus up to $17.5 million in additional proceeds from milestone-based warrants. The unregistered securities are being issued under Section 4(a)(2) and Regulation D exemptions and will require a resale registration statement within 15 days of closing.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-29
Item 8.01
The Company completed a forward sale offering of 14,000,000 shares of common stock on June 17, 2026, with an additional 2,100,000 shares issued via exercise of an underwriter option on June 26, 2026. This represents a dilutive equity issuance totaling 16.1 million shares at $23.12325 per share, generating substantial proceeds for the Operating Partnership. The forward sale structure with multiple underwriters and forward purchasers is characteristic of a large equity capital raise, which is material to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-29
Item 3.02
The registrant conducted an unregistered private offering of 230,757.640 Class I common shares for approximately $4.7 million, relying on Section 4(a)(2) and Regulation D/S exemptions as part of a continuous offering.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-29
EX-99.1
This press release announces a registered direct offering of 7,000,000 ADSs at $0.625 per share (gross proceeds ~$4.375 million) to a single institutional investor. The offering is registered under Form F-3 and represents a dilutive equity issuance. The company explicitly states it will use net proceeds for working capital and general corporate purposes, which is typical of capital-raising activity by smaller issuers. This is material to investors as it increases share count and dilutes existing shareholders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-06-29
The 6-K discloses the closing of a warrant exercise window resulting in the issuance of 177,267 ordinary shares at an average price of approximately USD $121.57 per share, increasing share capital by nominal DKK 177,267. This represents a dilutive equity issuance triggered by warrant exercises, which is material to shareholders as it increases the share count and dilutes existing ownership. The disclosure of specific share count, pricing, and capital increase aligns with dilutive_issuance classification.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-29
Item 3.02
AGL Private Credit Income Fund closed a sale of 1,289,767.84 common shares for $30,000,000 on June 26, 2026, pursuant to subscription agreements with shareholders under Section 4(a)(2) and Regulation D. This unregistered equity offering materially increases the share count and dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-06-29
Item 3.02
FibroBiologics completed a private placement on June 25, 2026, raising approximately $3.0 million in gross proceeds through the issuance of 4,081,633 shares of common stock (or pre-funded warrants) and series A and B warrants exercisable for up to 8,163,266 additional shares, with potential for up to $6.0 million in additional proceeds. The securities were issued under Section 4(a)(2) and Regulation D exemptions and have not been registered under the Securities Act, creating significant dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-29
Item 3.02
Blackstone Infrastructure Strategies L.P. completed unregistered private placements of limited partnership units totaling approximately $365 million across multiple unit classes (Class I, S, D, and ACC Units) to accredited investors and qualified purchasers under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-29
Item 3.02
Blackstone Private Equity Strategies Fund L.P. and its feeder fund completed unregistered sales of limited partnership units totaling approximately $992.9 million in aggregate consideration on June 1, 2026, to accredited investors and qualified purchasers under Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-29
Item 3.02
Scilex contemplates an unregistered private placement of Company Common Stock to Datavault, an accredited investor, in a transaction exempt under Section 4(a)(2) and Regulation D Rule 506, as part of the proposed Bitcoin acquisition transaction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-29
Item 3.02
The filing discloses an unregistered sale of 560,488.164 shares of Class I common stock for approximately $8.0 million, exempt under Section 4(a)(2) of the Securities Act and Regulation D. This is a classic dilutive equity issuance by a BDC raising capital through a private placement, which materially affects existing shareholders' ownership percentages and is a significant capital event for the registrant.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-29
Item 3.02
The Company issued 1,310,969 shares of common stock to ASPIS Cyber Technologies for $1.7 million under a Stock Purchase Agreement dated April 15, 2026, consummated on June 26, 2026. The issuance is explicitly exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, which are hallmarks of a private placement. This unregistered equity issuance is material to investors as it represents significant dilution and capital raising activity.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-29
EX-99.1
This press release announces the closing of a registered direct offering of 400,000 ADSs at $10.00 per ADS (a 10.7% premium to market) plus warrants to purchase 300,000 additional ADSs, raising $4.0 million gross proceeds. The offering was made pursuant to an effective Form F-3 shelf registration statement, making it a registered equity issuance. While registered offerings are technically not "unregistered" in the strict sense, this is a dilutive equity issuance that materially increases share count and is the type of capital-raising event that would affect a reasonable investor's assessment of ownership dilution and the company's financial position.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-06-29
The 6-K discloses a proposed private placement of 14,000,000 new ordinary shares at KRW 1,600 per share (total KRW 22.4 billion / HKD 113.6 million) to three subscribers including two individuals and a related entity. This is a dilutive equity issuance requiring shareholder approval at the August 10, 2026 EGM, with proceeds earmarked for working capital (procurement, marketing, R&D). The transaction materially dilutes existing shareholders and raises capital through unregistered equity sales.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-29
Item 3.02
Alpex completed an unregistered private placement of 187,500 Private Units to the Sponsor for $1,875,000 substantially concurrent with the IPO closing, with units subject to transfer restrictions until completion of the initial business combination.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-06-29
The Company issued 500,000 warrants to purchase ordinary shares at $6.25 per share to Taurus Mining Finance on June 29, 2026, pursuant to a waiver letter related to a $60 million senior secured bridge loan facility. This is a dilutive equity issuance tied to debt financing and represents a material capital structure event affecting existing shareholders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-29
EX-99.1
The press release announces the closing of a registered direct offering of 3,149,832 ordinary shares at $1.97 per share, generating approximately $6.2 million in gross proceeds. This is a registered equity issuance that dilutes existing shareholders. The offering was conducted pursuant to a shelf registration statement on Form F-3, making it a registered (not unregistered) offering, but it remains a material capital-raising event that increases share count and dilutes ownership. The company explicitly states use of proceeds for general corporate purposes, strategic expansion, and acquisition-related costs.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-29
Item 7.01
Creative Realities announced commencement of a public underwritten offering of common stock and pre-funded warrants, with an underwriter option for an additional 12.5% of shares. Proceeds will be used for working capital, debt paydown, and potential acquisitions under an effective Form S-3 shelf registration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-29
Item 3.02
Nexscient issued 816,000 restricted shares of common stock to two executive officers (President & CEO Fred Tannous and COO Tarek Shoufani) in settlement of $204,000 in accrued wages, relying on Section 4(a)(2) exemption from Securities Act registration. This is a classic unregistered equity issuance under Item 3.02, diluting existing shareholders. The transaction is material because it represents a significant equity grant to related parties and signals cash preservation concerns ahead of a planned uplisting.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-06-29
The filing discloses a registered direct offering of 11,038,767 shares of Class A common stock at $0.165 per share, generating approximately $1.8 million in gross proceeds. This is a material dilutive equity issuance under Item 1.01. While Item 5.02 also reports Alan Gaines' board resignation, the primary substantive event disclosed is the equity offering, which materially affects shareholder ownership and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-29
Item 1.01
U.S. GoldMining entered into a securities purchase agreement to issue 522,876 shares of common stock at $7.65 per share in a registered direct offering, generating approximately $4.0 million in gross proceeds. This is a registered equity issuance that dilutes existing shareholders and represents a material capital-raising event for the company, with proceeds designated for working capital and general corporate purposes.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-29
Item 3.02 discloses unregistered sales of common stock and warrant exercises during Q2 2026 under Section 4(a)(2) exemption, totaling approximately $7.36 million in gross proceeds. Item 7.01 provides detailed capital activity breakdown including multiple equity issuances at varying prices and warrant exercises. This represents a material dilutive equity issuance that would affect shareholder ownership and is a key indicator of capital-raising activity at a small-cap company.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-29
EX-99.1
Uxin announced the closing of a US$15 million investment involving the issuance of Class A ordinary shares at US$0.00953 per share to parties designated by NIO Capital under previously announced share subscription agreements. This is a partial closing of a larger US$50 million committed investment involving the issuance of 5,246,589,717 Class A ordinary shares. The transaction represents a dilutive equity issuance that would materially affect existing shareholders' ownership percentages and is therefore material to investors.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-06-29
SharonAI announced the closing of a US$1.6 billion strategic financing comprising (i) a private placement of approximately US$900 million in Class A Ordinary Common Stock and pre-funded warrants, and (ii) a US$700 million private placement of 4.75% Convertible Senior Notes due 2032. The equity component (6,719,896 shares plus 6,374,823 warrant shares) represents a material dilutive issuance to existing shareholders. While the filing also includes a debt component, the primary disclosed action is the closing of the equity private placement, which is a classic dilutive issuance event material to investors.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-06-29
Item 1.01
Oncotelic Therapeutics completed an unregistered sale of equity securities, including convertible promissory notes, as evidenced by the Securities Purchase Agreement and Convertible Promissory Note exhibits filed with the 8-K. This private placement represents a material capital-raising transaction that dilutes existing shareholders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-29
The 6-K discloses entry into an At-The-Market (ATM) Sales Agreement on June 25, 2026, permitting Youxin Technology to issue and sell up to $6,355,771 of Class A ordinary shares through Aegis Capital Corp. This is an unregistered equity issuance under a shelf registration (Form F-3), structured as an ATM offering. The disclosure explicitly describes the offering mechanics, commission terms (3.0%), and prospectus supplement filing. ATM offerings are classic dilutive issuances material to investors assessing capital structure and shareholder dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-26
Item 8.01
The filing discloses an increase in the amount available for sale under an At The Market (ATM) Offering Agreement by an additional $15,000,000 of common shares. The Company has already sold 1,804,444 shares for approximately $12.66 million since May 2024, and this new authorization substantially expands the dilutive issuance capacity. ATM offerings are classic dilutive equity issuances that signal capital-raising activity and shareholder dilution, particularly material for a small-cap company like Ascent Solar with only 9.8 million shares outstanding as of the filing date.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-26
Item 3.02
SmartKem issued 5,000 shares of Series A convertible preferred stock and 10,753,615 warrants in a private placement on June 22, 2026, raising approximately $4.0 million in cash under Section 4(a)(2) and Regulation D Rule 506.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-26
Item 8.01
Soligenix increased the maximum aggregate offering amount under an At Market Issuance Sales Agreement (ATM offering) by an additional $2,500,000 of common stock. The company had previously sold approximately $6,234,000 under the same agreement. ATM offerings are a classic form of dilutive equity issuance used by smaller public companies to raise capital, and the prospectus supplement filing establishes the legal framework for this dilutive offering.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-26
Item 8.01
An S-3 registration statement became effective for the resale of up to 87 million shares by selling stockholders, including 8.75 million shares from pre-funded warrants and 43.5 million shares from common warrants with a $1.20 exercise price, representing a substantial dilutive issuance to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-26
Item 1.01
REalloys completed a private placement of 7,017,540 shares of common stock at $14.25 per share, raising approximately $100 million in gross proceeds. The unregistered shares were issued under Section 4(a)(2) and Rule 506(b) exemptions to institutional and accredited investors, with the company agreeing to file a resale registration statement.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-06-26
KB Securities, a wholly-owned subsidiary of KB Financial Group, resolved on June 26, 2026 to increase its capital through issuance of 56,753,688 common shares at KRW 17,620 per share, generating approximately KRW 1 trillion in proceeds. This is a material capital raise by a significant subsidiary that will dilute existing shareholders' ownership and is disclosed as a discrete corporate action rather than a periodic financial report.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-26
Item 8.01
The Company has agreed to issue 3,453,237 common shares valued at $4,800,000 to settle and terminate an offtake agreement with Vox Royalty entities. This is a material issuance of equity securities as consideration for a contract termination, which will be registered on Form S-3. The substantial share count and dollar value represent a dilutive capital event that would materially affect investor assessment of ownership and capitalization.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-26
Item 3.02
Silver Point Private Credit Fund issued and sold 745,920 unregistered common shares for approximately $20 million pursuant to subscription agreements, relying on Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-26
Item 3.02
The filing discloses an unregistered sale of 8,677,493 common shares for $250 million on June 23, 2026, pursuant to capital drawdown notices to investors. This is a classic dilutive equity issuance exempt under Section 4(a)(2) and Regulation D, representing a material capital raise that would affect investor assessment of ownership dilution and the company's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-26
Item 3.02
The filing discloses an unregistered sale of 1,527,300.4964 common shares for $40 million on June 24, 2026, pursuant to capital drawdown notices. This is a classic dilutive issuance under Item 3.02, exempt from registration under Section 4(a)(2) and Regulation D. The $40 million capital raise is material to a trust-based investment vehicle and would affect investor assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-26
Item 3.02
The filing discloses an unregistered sale of 1,146,788.9908 common shares for $30,000,000 on June 24, 2026, pursuant to capital drawdown notices under Section 4(a)(2) and Regulation D/S exemptions. This is a classic dilutive equity issuance that would materially affect investor assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-26
Item 8.01
The Company issued 4,761,905 shares of common stock to Palantir Technologies as consideration for software license fees and professional services. This is a dilutive equity issuance registered under Form S-3, representing a material capital event that would affect shareholder ownership and the total mix of information available to investors regarding the Company's capitalization and obligations to Palantir.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-26
Item 3.02
Ondas Inc. conducted unregistered sales of equity securities to non-U.S. investors under Regulation S exemption, resulting in dilution to existing shareholders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-26
EX-99.1
This press release announces a registered direct offering of 400,000 ADSs at $10.00 per ADS (representing a 10.7% premium to market) for gross proceeds of $4.0 million, plus warrants to purchase 300,000 additional ADSs. The offering is being made pursuant to an effective Form F-3 shelf registration statement. This is a classic dilutive equity issuance to a strategic institutional investor, material to shareholders as it increases share count and dilutes existing ownership.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 72%
filed 2026-06-26
Item 1.02
The filing discloses termination of a securities purchase agreement for a $1,000,000 private placement of 666,667 units at $1.50 per unit. While the termination itself is the stated Item 1.02 event, the material substance is the failure of a planned dilutive equity issuance that would have raised significant capital. For a small-cap company like Firefly Neuroscience, the loss of this $1M financing is material to investor assessment of liquidity and capital structure, even though the agreement was terminated rather than completed.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-06-26
AIOS Tech entered into a share subscription agreement on June 26, 2026, under which Swift Prime Limited (owned by director and Co-CEO Guo Li) will subscribe for 5,000,000 Class B common shares at par value (US$0.0001 per share). Upon completion, Mr. Guo Li will beneficially own approximately 60.6% of outstanding shares and 99.4% of voting power. This is a material dilutive issuance of equity securities at a nominal price, resulting in a significant change of control and voting concentration that would materially affect a reasonable investor's assessment of the registrant.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-26
EX-99.1
The press release announces the closing of a registered direct offering of 673,006 common shares at CAD$3.74 per share, raising approximately CAD$2.5 million, plus a concurrent private placement of unregistered warrants. This is a classic dilutive equity issuance that increases share count and raises capital. The unregistered warrant component (issued under Section 4(a)(2) and Regulation D) is particularly characteristic of dilutive private placements at smaller issuers.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 72%
filed 2026-06-26
Item 8.01
Visa deposited $250 million into a litigation escrow account, triggering downward adjustments to conversion rates for class B-1, B-2, and B-3 common stock held by U.S. financial institutions. The filing explicitly states these conversion rate adjustments have "the same effect on earnings per share as repurchasing the Company's class A common stock," resulting in material dilution to the as-converted share counts (reduction of approximately 6,658 to 740,184 shares across the three classes). This is a dilutive capital event affecting shareholder equity and EPS, though the mechanism is conversion-rate adjustment rather than a traditional equity issuance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-06-26
Item 8.01
The Company announced an extension of a subscription rights offering to purchase common stock at $6.90 per share, with the new expiration date of July 15, 2026. This is a dilutive equity issuance that allows existing and new shareholders to purchase shares, which is material to investors as it affects share count and ownership dilution. While the extension itself is administrative, the underlying rights offering represents a material capital-raising activity that would affect a reasonable investor's assessment of the registrant's financing strategy and equity structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-26
Item 8.01
The disclosure announces a rights offering (subscription rights offering) that commenced June 8, 2026, allowing shareholders to purchase common stock at $6.90 per share. The filing announces that the transferable subscription rights will now trade on OTC Markets under ticker "LGLGR" beginning June 29, 2026, with an expiration date of July 15, 2026. This is a dilutive equity issuance that would materially affect shareholder ownership and is a capital-raising activity typical of the dilutive_issuance category.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 75%
filed 2026-06-26
The Company entered into a Debt Conversion Agreement on June 22, 2026, whereby it will issue 10,000,000 Class B ordinary shares to CEO Houqi Zhang in settlement of a $7,000,000 interest-free loan. This is a dilutive equity issuance in exchange for debt forgiveness. While the shares are subject to a three-year lock-up, the issuance itself represents a material capital event that dilutes existing shareholders and should be disclosed as a material transaction affecting the equity structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-26
The filing discloses a convertible promissory note issuance ($809,705.75 principal) that will automatically convert into common stock upon the pending Gravitics merger closing, with conversion shares subject to a 4.99% beneficial ownership limitation. While Item 1.01 frames this as a "material definitive agreement" and Item 2.03 addresses the debt obligation, the core material event is the dilutive equity issuance—the note's mandatory conversion into shares at $0.01966 per share represents a significant dilution to existing shareholders, particularly given the company's small size and the conversion mechanics tied to the merger.
View raw filing on EDGAR →